Evommune, Inc.
(EVMN)Financial Statements · SEC EDGAR XBRL
Revenue
$13.0M
+85.7%
Net Income
-$68.9M
-3.1%
EPS
$-11.22
+75.2%
Op. Income
-$81.1M
-15.8%
FCF
-$76.7M
-31.6%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)